Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that from October 1, 2017, LTL Pharma will succeed the marketing approval in Japan from Astellas, for “Nivadil® tablets 2mg, 4mg” (hypertension treatment), “Solantal® tablets 50mg, 100mg” (analgesia/anti-inflammatory), and “Lowgan® tablets 10mg” (hemodynamic improving type antihypertensive) (the “Products”) and Astellas will transfer the distribution rights of the Products in Japan to LTL Pharma.

On March 28, 2017, Astellas and LTL Pharma entered into an Asset Purchase Agreement, under which Astellas will transfer to LTL Pharma its marketing authorization of the Astellas’ 16 long-listed products in Japan, supply business of active pharmaceutical ingredients/bulk of the Products to third parties in and outside of Japan and royalty business of the products.

From October 2017, LTL Pharma will provide and collect information as the manufacturer and distributor in Japan and will ensure a stable supply of this product.

 

About LTL Pharma
LTL Pharma Co., Ltd. is a subsidiary of Japan Established Medicine Corporation (Head office: Tokyo). LTL Pharma handles long-listed drugs that have been prescribed for many years by many medical institutions. Together with Long-listed drugs, accumulated data concerning quality, efficacy and safety, LTL Pharma strives to ensure stable supply of products that maintain original product reliability.
LTL Pharma will contribute to the health of the patients as well as continue to maintain quality, ensure stable supply, and collect and provide safety information so that we can respond to the needs of patients who are taking the same medication over several years, and medical specialists who are familiar with the efficacy and the safety of these drugs.
For more information, please visit our website at www.ltl-pharma.com

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com.

 

Contact Information:

LTL Pharma Co. Ltd. LTL Pharma Call Center
TEL:: +81-(0)120-303-711
HP: www.ltl-pharma.com

Astellas Pharma Inc. Corporate Communications
TEL: +81-(0)3-3244-3201 FAX: +81-(0)3-5201-7473
HP: https://www.astellas.com